Plasma Adrenocorticotropin Concentration in Healthy Horses and in Horses With Clinical Signs of Hyperadrenocorticism

Couëtil, Laurent L.; Paradis, Mary Rose; Knoll, Joyce S.

doi:10.1111/j.1939-1676.1996.tb02016.x

Cited by 118 publications

(114 citation statements)

References 18 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…The sex predisposition of PPID is controversial, with no bias reported in some studies. 7,43 However, in a study of 217 horses, gelding sex was weakly associated with PPID. 31 In studies with fewer animals, female sex was associated with PPID.…”

Section: Discussionmentioning

confidence: 99%

“…23,35 Lymphoma (multicentric or alimentary) has also been reported as a reason for euthanasia of horses with PPID. 7,30 Weaknesses of the current study include its retrospective and diagnostic nature. Furthermore, all animals were patients in the Veterinary Teaching Hospital, which is a referral rather than primary care practice and may not represent the prevalence of disease in the regional or US equine population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What’s New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids

et al. 2015

View full text Add to dashboard Cite

Postmortem findings in 241 equids admitted to a teaching hospital that were at least 15 years old at autopsy were reviewed (1) to determine disease prevalence, (2) to compare the cause of death (or euthanasia) in equids 15 to 19 years of age (n ¼ 116) with that in equids 20 years of age (n ¼ 125), and (3) to catalog coexisting lesions in equids with pituitary pars intermedia dysfunction (PPID). Breed and sex were evenly distributed between the age groups. Death or euthanasia was attributed to disease of the digestive system (41.5%), pituitary gland (12.9%), locomotor system (10.0%), nervous system (7.9%), cardiovascular system (4.6%), urinary system (4.6%), reproductive system (4.2%), respiratory system (4.2%), integumentary system (4.2%), lymphoid system (2.5%), liver (2.5%), or systemic neoplasia (1.2%). Nervous system disease was more common in the 15-to 19-year group; urinary tract disease was more common in the 20-year group. Neoplastic disease, regardless of systemic location, was the basis for death or euthanasia in 18.7% of all equids. Squamous cell carcinoma, lymphoma, and melanoma were the most common malignant neoplasms. PPID was the most common specific diagnosis, based on the postmortem presence of hyperplasia or adenoma, and was the reason for euthanasia in 47.7% of 65 equids with PPID. The most common nonpituitary causes for death or euthanasia in equids with PPID were colic, lameness, cancer, and spinal cord disease. Coexisting conditions in equids with PPID that were not considered the basis for euthanasia included neoplasms, infections, lameness, and recurrent airway obstruction.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

What’s New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids

et al. 2015

View full text Add to dashboard Cite

show abstract

“…1,2 Common clinical signs of hirsutism, muscle wasting, polyuria, and polydipsia are associated with PPID and are accompanied by high plasma ACTH concentrations. 3 Pituitary pars intermedia dysfunction can be diagnosed by numerous methods. 4 The overnight dexamethasone suppression test (DST) is the most sensitive and specific diagnostic method; however, because of the purported infrequent association between corticosteroid administration and laminitis and the frequent existence of laminitis in affected horses, some clinicians prefer to use other tests.…”

mentioning

confidence: 99%

Treatment with Pergolide or Cyproheptadine of Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease)

Donaldson

LaMonte

Morresey

et al. 2002

Veterinary Internal Medicne

View full text Add to dashboard Cite

Medical records of 27 horses (including 13 ponies) treated with pergolide or cyproheptadine for pituitary pars intermedia dysfunction were reviewed to determine the effect of treatment on plasma ACTH, insulin, and glucose concentrations and clinical signs. Prior to treatment, the most common clinical signs were laminitis, hirsutism, and abnormal body fat distribution. The median pergolide dose was 3.0 g/kg PO q24h (range, 1.7-5.5 g/kg). All horses treated with cyproheptadine were given 0.25 mg/kg PO q24h. After pergolide treatment, ACTH concentrations (n ϭ 20; median ϭ 30.4 pg/ml; range, 4.2-173) were significantly lower (P Ͻ .01) than those in horses treated with cyproheptadine (n ϭ 7; median ϭ 141.0 pg/ml; range, 10-1,230). Among horses treated with pergolide, there was a correlation between ACTH concentration after treatment and the duration of treatment (P Ͻ .001) and pergolide dose (P ϭ .04). Significantly (P ϭ .02) more owners of horses treated with pergolide (85%, 17/20) reported an improvement in clinical signs compared to owners of horses treated with cyproheptadine (28%, 2/7).

show abstract

“…The proportion of mares (58 %) was higher than that of male horses (42 %) but no statistically significant sex difference was determined. Other studies did not show any sex predilection for developing PPID either (Breukink et al 1993, Couëtil et al 1996, Schott 2002.…”

Section: Discussionmentioning

confidence: 89%

Use of the chasteberry preparation Corticosal® for the treatment of pituitary pars intermedia dysfunction in horses

Bradaric¹,

May²,

Gehlen³

2013

PHK

View full text Add to dashboard Cite

SummaryThe objective of this study was to describe the efficacy of PPID treatment with the combined supplement corticosal ® containing chasteberry. Thirty-eight horses and ponies with PPID were devided into three groups and received either the chasteberry preparation (group T1) or pergolide in addition to the chasteberry preparation (group T2) for six months or pergolide in addition to a placebo for the first three months and pergolide in addition to the chasteberry preparation for the following three months (group T3). Clinical and laboratory examinations were performed at three times points. Within group T1, a significant difference in clinical parameters between the first and second examination (p = 0.0042) as well as between the second and third examinations (p = 0.0001) was observed. The clinical signs improved significantly based on the clinical overall score. On the basis of the collected data, beneficial effects of the chasteberry preparation corticosal ® on clinical parameters for PPID were determined.

show abstract

Plasma Adrenocorticotropin Concentration in Healthy Horses and in Horses With Clinical Signs of Hyperadrenocorticism

Cited by 118 publications

References 18 publications

What’s New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids

What’s New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids

Treatment with Pergolide or Cyproheptadine of Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease)

Use of the chasteberry preparation Corticosal® for the treatment of pituitary pars intermedia dysfunction in horses

Contact Info

Product

Resources

About